Metadoxine versus placebo for the treatment of non-alcoholic steatohepatitis: A randomized controlled trial

Journal of Clinical and Experimental Hepatology

Volumn 4, Issue 2, 2014, Pages 94-100

  Shenoy, Kotacherry T ^a,b   Balakumaran, Leena K ^b   Mathew, Philip ^c   Prasad, Mohan ^d   Prabhakar, Boddu ^e   Sood, Ajit ^f   Singh, Shivaram P ^g   Rao, Nagaraj P ^h   Zargar, Shoukat A ⁱ   Bignamini, Angelo A ^j  

^a GOVERNMENT MEDICAL COLLEGE   (India)

^b Population Health and Research Institute   (India)

^c PVS Memorial Hospital   (India)

^d KG Hospital and Post Graduate Medical Institute   (India)

^e OSMANIA MEDICAL COLLEGE   (India)

^f DAYANAND MEDICAL COLLEGE AND HOSPITAL   (India)

^g SCB Medical College   (India)

^h ASIAN INSTITUTE OF GASTROENTEROLOGY   (India)

ⁱ SHER I KASHMIR INSTITUTE OF MEDICAL SCIENCES   (India)

^j UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

Controlled clinical trial; Metadoxine; NASH

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; METADOXINE; PLACEBO;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOGRAPHY; FEMALE; HISTOLOGY; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 84904755522     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/j.jceh.2014.03.041     Document Type: Article

References (31)

1. Tolman K.G., Fonseca V., Dalpiaz A., Tan M.H. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007, 30:734-743.
2. Musso G., Gambino R., Cassader M., Pagano G. A meta-analysis of randomized trials for the treatment of non alcoholic fatty liver disease. Hepatology 2010, 52:79-104.
3. Boettcher E., Csako G., Pucino F., Wesley R., Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2012, 35:66-75.
4. Li W., Zheng L., Sheng C., et al. Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids Health Dis 2011, 10:49.
5. Calabrese V., De Bernardis E., Rizza V. Role of metadoxine in the control of the oxidative stress from acute and chronic ethanol intoxication. Boll Soc Ital Biol Sper 1986, 62:1357-1363. [Article in Italian].
6. Calabrese V., Calderone A., Ragusa N., Rizza V. Effects of metadoxine on cellular status of glutathione and of enzymatic defence system following acute ethanol intoxication in rats. Drugs Exp Clin Res 1996, 22:17-24.
7. Calabrese V., Randazzo G., Ragusa N., Rizza V. Long-term ethanol administration enhances age-dependent modulation of redox state in central and peripheral organs of rat: protection by metadoxine. Drugs Exp Clin Res 1998, 24:85-91.
8. Felicioli R., Saracchi I., Flagiello A.M., Bartoli C. Effects of pyridoxine-pyrrolidon-carboxylate on hepatic and cerebral ATP levels in ethanol treated rats. Clin Pharmacol Ther Toxicol 1980, 18:177-180.
9. Baldacci M., Catalani R., Bartoli C., Mura U. Effects of piridoxine pyrrolidone-carboxyalte on the liver levels of adenosine triphosphate in rats. Boll Soc Ital Biol Sper 1982, 58:1643-1649. [Article in Italian].
10. Arosio B., Santambrogio D., Gagliano N., Annoni G. Changes in expression of the albumin, fibronectin and type I procollagen genes in CCl4-induced liver fibrosis: effect of pyridoxol L, 2-pyrrolidon-5 carboxylate. Pharmacol Toxicol 1993, 73:301-304.
11. Annoni G., Contu L., Tronci M.A., Caputo A., Arosio B. Pyridoxol L, 2-pyrrolidon-5 carboxylate prevents active fibroplasia in CCl4-treated rats. Pharm Res 1992, 25:87-93.
12. Gutiérrez-Ruiz M.C., Bucio L., Correa A., et al. Metadoxine prevents damage produced by ethanol and acetaldehyde in hepatocyte and hepatic stellate cells in culture. Pharm Res 2001, 44:431-436.
13. Pal'tsev A.I., Sharapov I.V., Gorbunova E.N., et al. Non-alcoholic fatty liver disease: age peculiarities, breakthrough in pathogenetic therapy. Eksp Klin Gastroenterol 2009, 8:19-25. [Article in Russian].
14. Addolorato G., Ancona C., Capristo E., Gasbarrini G. Metadoxine in the treatment of acute and chronic alcoholism: a review. Int J Immunopathol Pharmacol 2003, 16:207-214.
15. Saverymuttu S.H., Joseph A.E.A., Maxwell J.D. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J 1986, 292:13-15.
16. Osawa H., Mori Y. Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical amplitudes. J Clin Ultrasound 1996, 24:25-29.
17. Brunt E.M., Janney C.G., Di Bisceglie A.M., Neuschwander-Tetri B.A., Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94:2467-2474.
18. Loomba R., Wesley R., Pucino F., et al. Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials. Clin Gastroenterol Hepatol 2008, 6:1243-1248.
19. Amrapurkar D.N., Amrapurkar A.D. Nonalcoholic steatohepaitis: clinicopathological profile. J Assoc Physicians India 2000, 48:311-313.
20. Agarwal S.R., Malhotra V., Sakhuja P., Sarin S.K. Clinical, biochemical and histological profile of nonalcoholic steatohepatitis. Indian J Gastroenterol 2001, 20:183-186.
21. Singh S.P., Nayak S., Swain M., et al. Prevalence of nonalcoholic fatty liver disease in coastal eastern India: a preliminary ultrasonographic survey. Trop Gastroenterol 2004, 25:76-79.
22. Sanyal A.J. Non-alcoholic fatty liver disease: a medical consequence of globalisation?. Indian J Gastroenterol 2001, 20:215-216.
23. Duseja A., Das R., Nanda M., et al. Nonalcoholic steatohepatitis in Asian Indians is neither associated with iron overload nor with HFE gene mutations. World J Gastroenterol 2005, 11:393-395.
24. Le T.A., Chen J., Changchien C., et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012, 56:922-932.
25. Noureddin M., Lam J., Peterson M.R., et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013, 58:1930-1940.
26. Caballería J., Parés A., Brú C., et al. Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. J Hepatol 1998, 28:54-60.
27. Malhotra P.S., Singh B.R., Narotam B., Kaur K.P. A study of metadoxine in alcoholic liver disease. J Assoc Physicians India 2005, 53:352-353.
28. Vedrova N.N., Gnezdilova NIu Metadoxyl in combined treatment of alcohol damage to the liver. Klin Med Mosk 2001, 79:56-58. [Article in Russian].
29. Fehér J., Lengyel G. A new approach to drug therapy in non-alcoholic steatohepatitis (NASH). J Int Med Res 2003, 31:437-451.
30. Váli L., Blázovics A., Fehér J. The therapeutic effect of metadoxine on alcoholic and non-alcoholic steatohepatitis. Orv Hetil 2005, 146:2409-2414. [Article in Hungarian].
31. Fehér J., Váli L., Blázovics A., Lengyel G. The Beneficial effect of metadoxine (pyridoxine-pyrrolidone-carboxylate) in the treatment of fatty liver diseases. CEMED 2009, 3:65-76.